Summary
Danaher Corporation's Q3 2017 report indicates robust top-line growth, with total revenues increasing by 9.5% year-over-year, driven by strong performance in its Life Sciences and Diagnostics segments. The company highlights a core revenue growth of 3.0% for the quarter, demonstrating underlying business expansion independent of acquisitions and currency fluctuations. High-growth markets, particularly China, were significant contributors to this growth, representing approximately 31% of total sales. Despite overall positive trends, the company incurred $76 million in restructuring and impairment charges related to discontinuing a molecular diagnostic product line, which is expected to yield annual savings of $40 million starting in 2018. Financially, Danaher is managing its liquidity effectively, with operating cash flows increasing by 8% for the first nine months of 2017. The company continues to strategically deploy capital through acquisitions, having acquired five businesses for $112 million in the first nine months of 2017, complementing its Life Sciences and Environmental & Applied Solutions segments. Management expresses confidence in its ability to fund operations, investments, and debt servicing, supported by strong operating cash flow and access to credit facilities.
Financial Highlights
52 data points| Revenue | $4.53B |
| Cost of Revenue | $1.99B |
| Gross Profit | $2.54B |
| R&D Expenses | $279.20M |
| SG&A Expenses | $1.50B |
| Operating Income | $759.20M |
| Interest Expense | $39.90M |
| Net Income | $572.10M |
| EPS (Basic) | $0.82 |
| EPS (Diluted) | $0.81 |
| Shares Outstanding (Basic) | 696.20M |
| Shares Outstanding (Diluted) | 705.60M |
Key Highlights
- 1Total revenues increased by 9.5% year-over-year for the third quarter of 2017, reaching $4.53 billion.
- 2Core revenue growth (excluding acquisitions and currency impact) was 3.0% for the quarter, indicating solid organic performance.
- 3High-growth markets led revenue growth, increasing at a high-single digit rate and contributing 31% of total sales in Q3 2017.
- 4The company incurred $76 million in restructuring and impairment charges related to discontinuing a molecular diagnostic product line, with expected annual savings of $40 million from 2018.
- 5Life Sciences and Diagnostics segments showed strong revenue growth, up 5.0% and 19.5% respectively, year-over-year for Q3 2017.
- 6Operating cash flow from continuing operations increased by 8.0% to $2.64 billion for the first nine months of 2017.
- 7Danaher completed five small acquisitions for a total consideration of $112 million in the first nine months of 2017, complementing existing business units.